15 unknown, 10 completed, 4 recruiting, 4 terminated. 25 Phase 2, 13 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Unknown 13, Completed 6, Recruiting 4, Terminated 2 |
| Phase 1 | 13 | Completed 5, Terminated 4, Recruiting 2, Unknown 2 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
Follow Theradex: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia Pacritinib, Hydroxyurea - Leukemia, Myelomonocytic, Chronic | Phase 2 | Recruiting | Theradex | 66 | 2026-01-01 | 2026-08-18 |
| Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors IO102-IO103, Pembrolizumab KEYTRUDA® - Melanoma, Squamous Cell Carcinoma of Head and Neck | Phase 2 | Recruiting | IO Biotech | 60 | 2023-12-21 | 2024-03-18 |
| A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes CTX-712 - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Recruiting | Chordia Therapeutics, Inc. | 225 | 2023-04-25 | 2026-04-13 |
| IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC IO102-IO103 in combination with pembrolizumab - Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma | Phase 2 | Completed | IO Biotech | 63 | 2022-04-11 | 2026-04-08 |
| Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO) ASTX727, Itacitinib, Ruxolitinib - MDS/MPN | Phase 1 / Phase 2 | Recruiting | Michael Savona | 94 | 2021-11-24 | 2026-04-21 |
| L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer L-DOS47, Doxorubicin - Pancreas Cancer | Phase 1 / Phase 2 | Terminated | Helix BioPharma Corporation | 28 | 2019-12-11 | 2025-05-06 |
| Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients Olaparib - Non-Germline BRCA Mutated Ovarian Cancer | Phase 3 | Completed | AstraZeneca | 279 | 2018-01-30 | 2024-08-21 |
| MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia MEN1703 - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Menarini Group | 73 | 2017-03-10 | 2025-04-29 |
| A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma ONCOS-102, Pemetrexed/cisplatin (carboplatin), Cyclophosphamide - To Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy | Phase 1 / Phase 2 | Unknown | Targovax Oy | 31 | 2016-06-01 | 2020-10-08 |
| An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3) VB10.16 Immunotherapy (DNA vaccine) - High Grade Cervical Intraepithelial Neoplasia | Phase 1 / Phase 2 | Completed | Nykode Therapeutics ASA | 34 | 2015-08-01 | 2022-07-13 |
| A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC L-DOS47 - Non-Small Cell Lung Cancer | Phase 1 | Terminated | Helix BioPharma Corporation | 14 | 2015-04-20 | 2024-06-03 |
| A Study of VLX1570 and Dexamethasone in Myeloma Patients VLX1570 and dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Vivolux AB | 15 | 2015-04-08 | 2018-05-11 |
| Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors VLX600 - Refractory Cancer | Phase 1 | Terminated | Vivolux AB | 19 | 2015-02-18 | 2018-05-11 |
| A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma HF10 plus Ipilimumab - Malignant Melanoma | Phase 2 | Completed | Takara Bio Inc. | 46 | 2014-04-30 | 2018-09-26 |
| LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab LTX-315 consecutive lesions, LTX-315, LTX-315 + ipilimumab - Cancer, Melanoma | Phase 1 | Completed | Lytix Biopharma AS | 80 | 2013-11-01 | 2018-10-03 |
| The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055) Elacytarabine for infusion - Relapsed/Refractory AML | Phase 1 | Completed | Clavis Pharma | 43 | 2010-10-01 | 2013-09-23 |
| A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients Heat killed whole cell M. obuense (IMM-101) 0.1 mg, Heat-killed whole cell M.obuense (IMM-101) 0.5 mg, Heat killed whole cell M.obuense (IMM-101) 1.0 mg - Melanoma | Phase 1 | Completed | Immodulon Therapeutics Ltd | 19 | 2010-03-01 | 2012-12-06 |
| A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia Elacytarabine plus idarubicin - Acute Myeloid Leukemia | Phase 2 | Completed | Clavis Pharma | 51 | 2009-12-01 | 2013-09-27 |
| Paclitaxel in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer paclitaxel-loaded polymeric micelle - Pancreatic Cancer | Phase 2 | Completed | Theradex | 43 | 2005-05-01 | 2011-12-14 |
| Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse filgrastim, rituximab, cisplatin - Lymphoma | Phase 2 | Unknown | Theradex | 2003-04-01 | 2009-07-07 |
Showing 20 of 33. Sign in to see all of them.
Leukemia, Myeloid, Acute (4) · Lymphoma (4) · Melanoma (4) · Neoplasms (4) · Pancreatic Neoplasms (4) · Lymphoma, Follicular (3) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, Large-Cell, Immunoblastic (3) · Breast Neoplasms (2) · Burkitt Lymphoma (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Head and Neck Neoplasms (2) · Kidney Neoplasms (2) · Lymphoma, Non-Hodgkin (2)
Paclitaxel (4) · docosahexaenoyl-paclitaxel (4) · Cisplatin (3) · pembrolizumab (3) · 5'-oleoyl cytarabine (2) · BBR 3464 (2) · Carboplatin (2) · Cytarabine (2) · IDN 5109 (2) · Ipilimumab (2) · Methylprednisolone (2) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (1) · Biological Products (1) · Cyclophosphamide (1) · Decitabine (1)
United States (27) · United Kingdom (7) · Spain (6) · France (4) · Germany (4) · Canada (3) · Italy (3) · Norway (3) · Belgium (2) · Denmark (2) · Netherlands (2) · Poland (2) · Australia (1) · Austria (1) · Bulgaria (1)
Ross C. Donehower, MD (2) · Aaron Mansfield, MD (1) · Arlene A. Forastiere, MD (1) · Barbara Burtness, MD, Prof (1) · Chris Wilks (1) · David A Rizzieri, MD (1) · David Paul Kelsen, MD (1) · Edith A. Perez, MD (1) · Elizabeth Johnson, MD (1) · Erkut Borazanci, MD (1) · George L. Miller, MD (1) · Guillermo Garcia-Manero, MD (1) · James Spicer, MD, PhD (1) · John S. MacDonald, MD (1)
PMID 19968498, PMID 21930686, PMID 24433865, PMID 29896663, PMID 31177991, PMID 31553234, PMID 33542073, PMID 35063276, PMID 36129459, PMID 39695768, PMID 41056522, PMID 41536779, PMID 42013378
2009 (1), 2015 (1), 2017 (1)